Midlands Partnership NHS Foundation Trust Children & Young People Covid Vaccination Programme

12-15covidimms@mpft.nhs.uk

Autumn Covid Vaccination Programme

November 2022

Dear Parent / Guardian

The CYP Covid Vaccination team are carrying out a community clinic at **Rugeley Fire Station**, **WS15 2FX on Sunday 6**th **November 2022** between 10am and 2:45pm to administer Covid vaccinations. This includes 1st dose, 2nd dose and autumn boosters to those children between the ages of 5 and 11 if they are eligible.

If your child is aged between 12 and 17 we are able to administer 1st and 2nd doses – autumn boosters to those children that are eligible for a booster. Your child is eligible if:

- They are aged between 5 years and 17 years (had to be 5 years old on or before 31st August 2022).
- · Have not received a Covid vaccination before.
- · If had a 1st dose needs to be 12 weeks before 2nd dose (8 weeks if Clinically vulnerable).
- They live with someone who is immunosuppressed** (see table below).
- Had 2nd vaccine 12 weeks prior and now require an Autumn booster only clinically vulnerable or living with someone immunosuppressed or someone age 16 or 17 years who are carers.
- · Have not had Covid 19 infection within last 12 weeks (28 days if clinically vulnerable).
- · Consent needs to be given by a parent or guardian with parental responsibility or delegated authority.

PARENTAL RESPONSIBILITY:

The person(s) with parental responsibility will usually, but not always, be the child's birth parents. People with parental responsibility for the child include: the child's mother; the child's father if married to the mother at the child's conception, birth or later; a legally appointed guardian; the local authority if the child is on a care order; or a person named in a residence order in respect of the child. Fathers who have never been married to the child's mother will only have parental responsibility if they acquired it through a court order or parental responsibility agreement.

After the 30th November 2003 unmarried fathers have automatic parental responsibility for their children if they are named on the birth certificate. For a child born before the 30th November 2003, they can be reregistered and the father named on the birth certificate, after which the father will have automatic parental responsibility.

DELEGATED AUTHORITY:

In particular circumstances, the person(s) who hold(s) parental responsibility may have given delegated authority to a foster carer to be able to give consent for immunisations. Where a foster carer does not hold delegated authority for immunisations please arrange for the local authority to complete and sign the enclosed form.

Table 4 *Clinical and other risk groups for children and young people aged 5-15 years

Chronic Respiratory disease	Including those with poorly controlled asthma that requires continuous or repeated use of systemic steroids or with previous exacerbations requiring hospital admission, cystic fibrosis, ciliary dyskinesias and bronchopulmonary dysplasia
Chronic heart conditions	Haemodynamically significant congenital and acquired heart disease, or less severe heart disease with other co-morbidity. This includes:

	single ventricle patients or those palliated with a Fontan (Total
	Cavopulmonary Connection) circulation
	• those with chronic cyanosis (oxygen saturations <85% persistently)
	· patients with cardiomyopathy requiring medication
	patients with congenital heart disease on medication to improve heart
	function
	• patients with pulmonary hypertension (high blood pressure in the lungs)
	requiring medication
Chronic conditions of	Including those associated with congenital malformations of the organs,
the kidney, liver or	metabolic disorders and neoplasms, and conditions such as severe
<u> </u>	
digestive system	gastrooesophageal reflux that may predispose to respiratory infection
Chronic Neurological	This includes those with
disease	 neuro-disability and/or neuromuscular disease that may occur as a result of
	conditions such as cerebral palsy, autism, epilepsy and muscular
	dystrophy
	 hereditary and degenerative disease of the nervous system or muscles,
	other conditions associated with hypoventilation
	• severe or profound and multiple learning disabilities (PMLD), Down's
	syndrome, including all those on the learning disability register
	neoplasm of the brain
Fuel a suite a elia a uel a ue	
Endocrine disorders	Including diabetes mellitus, Addison's and hypopituitary syndrome
Immunosuppression**	Immunosuppression due to disease or treatment, including:
	• those undergoing chemotherapy or radiotherapy, solid organ transplant
	recipients, bone marrow or stem cell transplant recipients
	genetic disorders affecting the immune system (e.g. deficiencies of
	IRAK-4 or NEMO, complement disorder, SCID)
	those with haematological malignancy, including leukaemia and
	lymphoma
	those receiving immunosuppressive or immunomodulating biological
	therapy
	 those treated with or likely to be treated with high or moderate dose corticosteroids
	those receiving any dose of non-biological oral immune modulating
	drugs e.g. methotrexate, azathioprine, 6-mercaptopurine or
	mycophenolate
	those with auto-immune diseases who may require long term
	immunosuppressive treatments
	Children who are about to receive planned immunosuppressive therapy
	should be considered for vaccination prior to commencing therapy
Asplenia or	Including hereditary spherocytosis, homozygous sickle cell disease and
dysfunction of the	thalassemia major
· ·	i italassettila itiajui
spleen	Including with about all discuss and about a confidence and the confid
Serious genetic	Including mitochondrial disease and chromosomal abnormalities
abnormalities that	
affect a number of	
systems	
Pregnancy Other risk groups	All stages (first, second and third trimesters)

**Household contacts of people with immunosuppression Individuals who expect to share living accommodation on most days (and therefore for whom continuing close contact is unavoidable) with individuals who are immunosuppressed (defined as immunosuppressed in table's 3 or 4).

Table 3 - Immunosuppression due to disease or treatment, including patients undergoing chemotherapy leading to immunosuppression, patients undergoing radical radiotherapy, solid organ transplant recipients, bone marrow or stem cell transplant recipients, HIV infection at all stages, multiple myeloma or genetic disorders affecting the immune system (e.g. IRAK-4, NEMO, complement disorder, SCID).

Individuals who are receiving immunosuppressive or immunomodulating biological therapy including, but not limited to, anti-TNF, alemtuzumab, ofatumumab, rituximab, patients receiving protein kinase inhibitors or PARP inhibitors, and individuals treated with steroid sparing agents such as cyclophosphamide and mycophenolate mofetil.

Individuals treated with or likely to be treated with systemic steroids for more than a month at a dose equivalent to prednisolone at 20mg or more per day for adults.

Anyone with a history of haematological malignancy, including leukaemia, lymphoma, and myeloma.

Those who require long term immunosuppressive treatment for conditions including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, scleroderma and psoriasis.

Some immunosuppressed patients may have a suboptimal immunological response to the vaccine (see Immunosuppression and HIV).

If you have any queries please contact the team on 12-15covidimms@mpft.nhs.uk

Kind Regards,

Kylie Ekin – Admin Support CYP Covid Vaccination Programme

Telephone Number: 01283 352083

Email: kylie.ekin@mpft.nhs.uk and 12-15covidimms@mpft.nhs.uk